πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

5,609 results for β€œAB” Clear

  1. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  2. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Amifampridine Phosphate 10 MG Oral Tablet

    CATALYST PHARMACEUTICALS, INC.

    Spinal Muscular Atrophy Type 3

    phase 2 small molecule terminated

    1 trial

  4. Amimox 500 mg filmdragerade tabletter, KΓ₯vepenin 800 mg filmdragerade tabletter

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  5. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  6. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  7. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  8. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  9. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  10. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  11. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  12. An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

    Swedish Orphan Biovitrum AB (publ)

    Transplant-associated Thrombotic Microangiopathy (TA TMA)

    phase 2 other active

    1 trial

  13. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  14. An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent Ξ±- or Ξ²-thalassemia or low-risk myelodysplastic syndromes

    Lacuna Pharma Pty Ltd

    transfusion-dependent Ξ±- or Ξ²-thalassemia or low-risk myelodysplastic syndromes

    phase 2 other active

    1 trial

  15. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  16. Andecaliximab

    Gilead Sciences Ireland UC

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  17. Anlotinib and Sintilimab injection

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  18. Anrotinib plus Tirelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  19. Anti-PD-1 antibody drug named Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IV HCC

    phase 2 small molecule active

    1 trial

  20. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  21. Antimicrobial agent

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Ulcers (DFUs)

    phase 2 small molecule active

    1 trial

  22. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  23. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  24. Apatinib mesylate tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources